PIK3CG and hematologic disorder: Our data thus demonstrate that the novel analog #26 forms the basis of a platform for the development of targeted small-molecule therapeutics for treatment of EBV-positive, and hematologic malignancies in early phase clinical trials with comparative efficacy to current PI3K inhibitors in terms of their potency, but with specificity for PI3Kγ.